MaxCyte, Inc. Total Voting Rights (5575A)
June 02 2021 - 4:18AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 5575A
MaxCyte, Inc.
02 June 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Total Voting Rights
Gaithersburg, Maryland - 2 June 2021: MaxCyte (LSE: MXCT, MXCN),
the global cell-based medicines and life sciences company,
announces that pursuant to its block admission facility, details of
which were announced on 2 May 2017, it has recently issued 34,722
shares of common stock, $0.01 par, of the Company ("Common Stock")
in satisfaction of the exercise of share options.
The new Common Stock will rank pari passu with the existing
shares of common stock of the Company. The total issued stock
capital of the Company following the recent issue of the new Common
Stock is 84,719,345 shares of Common Stock. Shareholders in the
Company may use this figure as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the stock capital of
the Company.
The number of unrestricted shares of Common Stock trading under
the symbol 'MXCT' is 84,389,345 a nd the number of restricted
shares of Common Stock trading under the symbol 'MXCN' will be
330,000.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Accounting Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison /
Samira Essebiyea
Corporate Broking
Nick Adams +44 (0) 20 7710 7600
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. MaxCyte's existing
customer base ranges from large biopharmaceutical companies,
including all of the top 10, and 20 of the top 25, pharmaceutical
companies based on 2020 global revenue, to hundreds of
biotechnology companies and academic centers focused on
translational research. MaxCyte has granted 13 strategic platform
licences to commercial cell therapy developers. Including these
strategic platform licences, MaxCyte has granted research and
clinical licences with academic and industry customers covering
over an estimated 140 programs, and clinical licences with academic
and industry customers covering over an estimated 100 programs
being developed for use in humans. MaxCyte was founded in 1998 and
is headquartered in Gaithersburg, Maryland, US. For more
information, visit www.maxcyte.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRDKBBDFBKKPAK
(END) Dow Jones Newswires
June 02, 2021 04:18 ET (08:18 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Aug 2023 to Aug 2024